Navigation Links
Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Date:12/14/2007

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin. The study, performed by principal investigator Federico A. Monzon, M.D., and colleagues from the University of Pittsburgh, Virginia Commonwealth University and Stanford University, examined the analytical performance characteristics and reproducibility of the Tissue of Origin Test.

There are an estimated 200,000 cancer patients with an uncertain primary diagnosis on their cancers each year in the U.S.(1),(2),(3) These people may benefit from additional diagnostic information to determine the tissue of origin for their cancer. One study showed that, in such cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

The Pathwork Tissue of Origin Test measures the expression of more than 1600 genes and compares a tumor's gene expression "signature" against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix microarray platform.

In the study, 60 archived tissue specimens from poorly and undifferentiated tumors (metastatic and primary) were analyzed at four laboratories representing a wide range of pre-analytical conditions. Reproducibility was analyzed by cross-wise comparisons of all 4 sites. Cross-laboratory comparisons, performed using a variety of measures, showed highly reproducible results betwe
'/>"/>

SOURCE Pathwork Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...ERFIELD, Ill., May 8 /- Sie...ica(R) Holdings (LabCorp(R)) today announced,that ...cuss future,possibilities to co-develop new clinic...nostics, metabolic syndrome, oncology and diabetes...cus on developing new tests that,could make the bi...
(Date:5/8/2008)...morial Sloan-Kettering Cancer Center Investigators...ive Ovarian Cancer Patients -, BRISBANE, Calif., ...nnounced the expansion of Phase 2 clinical trial p...cancer. This is the third major clinical trial,of ...hs, expanding on,on-going trials in breast and bra...
(Date:5/7/2008)... Study to Evaluate Preferred Induction Dosing...- Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) to...als, a,division of Wyeth (NYSE: WYE ), has commen...rial of TRU-015 in patients with rheumatoid arthri...rmaceuticals is developing,TRU-015, SBI-087 and ot...
(Date:5/7/2008)...III Data Presented at American Psychiatric Associa...e-FirstCall/ -- Forest Laboratories, Inc.,(NYSE: ...pro (escitalopram,oxalate) significantly improved ...tment and was well tolerated in adolescents, aged ...ding to phase III data presented at,the 2008 Annua...
Breaking Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 2Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 5Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 6New Drug Duo Helps Fight Colon Cancer 16802 1New Drug Duo Helps Fight Colon Cancer 16802 2New Drug Duo Helps Fight Colon Cancer 16802 3New Drug Duo Helps Fight Colon Cancer 16802 4Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 4592 1Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 4592 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 4592 3ANX 530 Demonstrates Equivalent Pharmacokinetics to Navelbine 28R 29 in a Registrational Bioequivalence Clinical Study 4589 1ANX 530 Demonstrates Equivalent Pharmacokinetics to Navelbine 28R 29 in a Registrational Bioequivalence Clinical Study 4589 2ANX 530 Demonstrates Equivalent Pharmacokinetics to Navelbine 28R 29 in a Registrational Bioequivalence Clinical Study 4589 3ANX 530 Demonstrates Equivalent Pharmacokinetics to Navelbine 28R 29 in a Registrational Bioequivalence Clinical Study 4589 4ANX 530 Demonstrates Equivalent Pharmacokinetics to Navelbine 28R 29 in a Registrational Bioequivalence Clinical Study 4589 5Presentation of HeartWare Clinical Results 1784 1Presentation of HeartWare Clinical Results 1784 2
...LOUISVILLE, Colo., June 26, 2007 /PRNewswire-First...rom three Phase I trials,studying REP8839, a novel... activity against major skin pathogens including,m... of the Phase I,trials show that topically applied...ed with low systemic exposure, or drug,absorption ...
... Canadian Biotechnology Company updates progress a...ALGARY, June 26, 2007 /PRNewswire-FirstCall/ - Sem...eloping a portfolio of,therapeutic proteins for me...d positive preclinical data supporting the,develop...he Company,presented its findings at the 67th Scie...
Other Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:5/11/2008)...NGTON, May 11 /PRNewswire-USNewswire/ -- Today, a ... American Red Cross relief supplies,touched down i...Nargis.,This newly arrived shipment includes an in... nets to help prevent the spread of malaria., "Th...exposed to the,elements and vulnerable to diseases...
(Date:5/10/2008)...ization Continues with Efforts to Gain Clearance f...upplies, STAMFORD, Conn., May 10 /PRNewswire-USNe...rrived in Myanmar earlier today to assess the,cris...learance for the,organization,s airlift of 15 tons...ngon., "AmeriCares is working closely with the Wo...
(Date:5/9/2008)...ORD, Mass., May 7 /PRNewswire-FirstCall/ -- Cynosu... manufacturer of a broad array of,light-based aest...as,received market approval from the Korea Food & ...de(TM) workstation for the removal of pigmented,le...the Accolade is the third,Cynosure flagship produc...
(Date:5/9/2008)...IEGO, May 9 /PRNewswire/ -- Summary: With the rece...ated 100,000 deaths and leaving over a,million peo...Internet,entrepreneurs Sharon Tucci and Steve Jone...s effort to award awareness for humanitarian needs...le. Setting an initial goal,of having 1,000 indivi...
Breaking Medicine News(10 mins):Health News:Relief Supplies from American Red Cross Arrive in Myanmar 2Health News:AmeriCares Relief Worker Arrives in Myanmar 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:New Web Site to Raise Awareness for the Myanmar Crisis Has Lofty Goals 2
... new biological function for a soccer ball-shaped .... A research team has found that buckyball has th...rogress of new therapies for allergy possible. All...ixth leading cause of chronic disease in the Unite...
...ertain bacteria that break down pollutants do thei...ning up toxic wastes. Research was conducted on th... models. Bacteria called Dehalococcoides ethenoge... in 1997 by James Gossett, Cornell professor of ci...
...S parents face fines and jail time if teenage chil...adult supervision. A Virginia couple who provided...ay party to stop him from drinking behind their ba...hol for under 21s, and were sent to jail for two y...
... brief encounter with a Jewish prostitute might ha...st, according to a new study by psychiatrists. Hi...ly untreated, led to his madness and eventually ta... the mentally retarded. There is "ample circumsta...
Other Medicine News:Health News:Buckyball Has the Ability to Fight Against Allergy: Research 2Health News:Insilico Studies on Chlorine Eating Bacteria 2Health News:US Parents Risk Jail When Their Teens Drink at Parties 2Health News:Hitler's Holocaust may Have Stemmed from Syphilis from Jewish Prostitute 2
... AliMed® Turnbuckle Elbow Orthosis applies dyn...or flexion. Controls elbow contracture in patients... strength. Also good for elbow flexion and extensi... tightened to apply tension (but not torque) to th...
... Innovative Aircast aircell technology enables the...ounts! Using a single pre-inflated aircell, the Ar...ensor muscle, not around the arm, for more support...ersatility, the Armband is designed to conform to ...
... The Cryo/Cuff for Walking Brace is designed to ad...rcast PneumaticWalker™ (sold separately). Wh...th cold water, the cuff surrounds the foot and ank...hemarthrosis, swelling, and pain.,All Cryo/Cuffs ...
The Bledsoe Extender Arm Brace is designed to handle post-op elbow arthroscopy, severe elbow strains and ligament trauma. The Bledsoe Extender Arm Brace should be used when limited R.O.M. or locked c
Medicine Products: